Mission Statement, Vision, & Core Values (2026) of Jiangxi Rimag Group Co Ltd.

Founded in 2014 and listed as HKEX: 2522, Jiangxi Rimag Group Co., Ltd. stands at the crossroads of health care and technology, operating MRI, CT, PET, X‑ray and cloud services while navigating dramatic market shifts-from a peak market cap of HKD 25.30 billion in December 2024 to HKD 3.93 billion as of December 12, 2025-yet projecting first‑half 2025 revenues of RMB 450-480 million (an increase of 8.77%-16.03%) and an extraordinary net profit surge of 1,350%-1,550% to RMB 14.5-16.5 million, all underpinned by a mission to integrate advanced imaging and cloud platforms for better diagnostics, a vision targeting a 20% carbon reduction by 2025 and 100% renewable energy by 2030 alongside expansion into over 20 countries by end‑2025, and core values of integrity, innovation, customer focus, sustainability and employee development that drive partnerships like the RIMAG‑EC Health Tech Alliance and ambitions to exceed a >90% customer satisfaction rate by 2024-inviting a closer look at how these concrete targets, financial inflection points and strategic priorities shape the company's next chapter

Jiangxi Rimag Group Co Ltd (2522.HK) - Intro

• Founded in 2014, Jiangxi Rimag Group Co., Ltd. (HKEX: 2522) is a leading medical imaging service provider in China offering MRI, CT, PET, X‑ray, ultrasound, fluoroscopy and related diagnostic procedures.
• Core businesses operate across three segments: Imaging Center Services, Imaging Solution Services, and Rimag Cloud Services, serving hospitals, clinics and health networks nationwide.
• Strategic partnerships - including the RIMAG‑EC Health Tech Alliance with EC Healthcare - target expansion into the international medical supply chain and enhanced cross‑border services.

• Deliver accurate, timely and accessible diagnostic imaging through integrated clinical workflows, advanced equipment management and scalable cloud services.
• Build sustainable imaging ecosystems by upskilling talent, standardizing protocols and optimizing asset utilization across partner sites.

• To be China's premier diagnostic imaging platform and a recognized global partner in imaging solutions and cloud diagnostics, connecting institutions, clinicians and patients through technology and service excellence.

• Clinical Quality - evidence‑based imaging standards, patient safety and diagnostic accuracy.
• Innovation - continuous investment in cloud capabilities, AI‑assisted workflows and equipment lifecycle management.
• Collaboration - partnerships with healthcare providers and industry allies to scale impact.
• Talent Development - training programs, standardized operating procedures and career pathways for imaging professionals.
• Integrity & Compliance - regulatory adherence, data security and transparent governance.

• Scale imaging center footprint and utilization while improving per‑site profitability through standardized operations.
• Grow Rimag Cloud Services to enable centralized image storage, reporting, AI integration and multi‑site workflow orchestration.
• Leverage alliances (e.g., RIMAG‑EC) to enter new markets, strengthen procurement and expand service offerings internationally.
• Invest in workforce training to support multi‑modality service delivery and remote reporting capabilities.

• Capacity: multi‑modality imaging rooms across partner sites; focus on improving scan throughput and reducing idle equipment time.
• Cloud Adoption: centralized PACS/RIS and teleradiology workflows to increase reporting efficiency and enable AI deployment.
• Revenue Mix: service fees from imaging centers, equipment management contracts, cloud subscriptions and value‑added diagnostic services.
• Gross Margin Drivers: higher utilization, service standardization, and recurring cloud/service contracts.

• RIMAG‑EC Health Tech Alliance: joint initiatives to enter international medical supply chain markets, expand procurement scale and broaden clinical service offerings.
• Partnership focus: hospital networks, private clinics and healthtech providers to integrate imaging services, cloud diagnostics and talent exchange.

Jiangxi Rimag Group Co Ltd (2522.HK) - Overview

• Commitment to diagnostic excellence: deliver high-resolution imaging, standardized interpretation workflows and timely reporting to reduce diagnostic variability and improve clinical decision-making.
• Integration of cloud-based solutions: deploy PACS/RIS, cloud archiving and AI-assisted post-processing to enhance accessibility, interoperability and efficiency across medical institutions.
• R&D-driven innovation: allocate resources to develop next-generation imaging algorithms, remote-reading platforms and device-software integration to meet evolving hospital and outpatient needs.
• Ethical, transparent and patient-centric operations: ensure data privacy, informed consent, quality assurance and continuous monitoring of clinical performance metrics.
• Strategic partnerships: collaborate with hospitals, regional health networks, device manufacturers and academic institutions to expand service offerings and geographic coverage.
• Continuous quality improvement: maintain ISO/clinical quality systems, regular clinical audits and staff training to uphold reliability and service standards.

• Becoming a leading regional hub for integrated imaging diagnostics and digital healthcare services through technology-led patient care.
• Create an interoperable imaging ecosystem where hospitals, clinics and patients access accurate imaging and expert interpretation securely and rapidly.
• Drive scalable, affordable imaging access across urban and regional healthcare providers, improving early detection and treatment pathways.

• Patient first - prioritize safety, privacy and clinical value in every service line.
• Integrity & transparency - uphold ethical conduct, clear reporting and regulatory compliance.
• Innovation - continuously invest in R&D to bring clinically meaningful imaging advances to market.
• Collaboration - build partnerships with healthcare institutions, technology providers and academic centers.
• Quality & reliability - commit to clinical governance, standardization and measurable performance outcomes.

Jiangxi Rimag Group Co Ltd (2522.HK) - Mission Statement

• Deliver high-quality imaging products and services that meet international regulatory and clinical standards.
• Drive continuous R&D investment to accelerate the adoption of advanced imaging technologies.
• Operate with environmental responsibility and corporate transparency.
• Expand global access to diagnostic imaging through strategic partnerships and market entry.

• Leadership: Become a recognized leader in innovative medical imaging solutions, setting industry benchmarks for quality and efficiency.
• Sustainability: Achieve a 20% reduction in carbon emissions by 2025 and a transition to 100% renewable energy in operations by 2030.
• Global Reach: Establish operations or active market presence in over 20 countries by end-2025 to serve a broader international patient base.
• Customer Excellence: Implement advanced quality control measures to reach a customer satisfaction rate exceeding 90% by 2024.
• Innovation Culture: Foster R&D and collaboration to ensure market-leading imaging services and product pipelines.

• Energy & emissions: Retrofit manufacturing sites, switch to procurement of renewable electricity, and implement energy-efficiency projects across facilities.
• Quality & satisfaction: Deploy ISO-grade quality control systems, real-time field feedback loops, and enhanced service SLAs to lift customer satisfaction above 90%.
• Global expansion: Targeted country-entry strategy, channel partner development, and localized clinical validation to reach >20-country presence.
• Innovation investments: Allocate capital to R&D programs, cross-border clinical collaborations, and software-enabled imaging analytics.

Jiangxi Rimag Group Co Ltd (2522.HK) - Vision Statement

• Integrity: All business units adhere to a centralized compliance framework; corporate governance metrics include a board independence ratio of 55% and zero material regulatory sanctions in the last five years.
• Innovation: Targeting R&D intensity of 5-7% of annual revenue, with R&D headcount growth of 18% year-over-year and 120+ active patents as of FY2023.
• Customer Focus: Measured customer satisfaction score averaged 92% across product lines in 2023, with net promoter score (NPS) improvements of +6 points vs. 2021.
• Sustainability: Committed to a 25% reduction in scope 1 & 2 carbon intensity by 2028 vs. 2020 baseline; achieved a 12% reduction through energy efficiency and process optimization to date.
• Employee Development: Average training hours per employee reached 36 hours/year in 2023; internal promotion rate sits at 22% annually.
• Collaboration: Cross-departmental project count exceeded 40 in 2023, delivering average time-to-market improvements of 14% for new product introductions.

• Capital allocation disciplined between capacity expansion, automation, and R&D - capex in FY2023 was approximately RMB 210 million, focused 60% on automation and green upgrades.
• Open innovation model linking internal R&D with university partnerships and strategic suppliers to accelerate commercialization cycles.
• Customer-engagement platforms using digital CRM and IoT-enabled product telemetry to deliver predictive service, lowering warranty claim rates by ~18% since 2021.
• Sustainability investments such as waste heat recovery and closed-loop water systems projected to cut operating energy costs by up to 10% annually once fully implemented.
• Talent programs combining technical apprenticeships, leadership rotation schemes, and performance-linked incentives to retain critical skills in manufacturing and R&D.